Extended indication Tizveni in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the
Therapeutic value No estimate possible yet
Total cost 11,182,500.00
Registration phase Registered

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information